Inari Medical's (NARI) Neutral Rating Reiterated at BTIG Research

BTIG Research restated their neutral rating on shares of Inari Medical (NASDAQ:NARI - Free Report) in a report published on Wednesday morning,Benzinga reports.

Several other analysts have also issued reports on NARI. Needham & Company LLC reiterated a "hold" rating on shares of Inari Medical in a report on Tuesday, October 29th. Oppenheimer assumed coverage on Inari Medical in a research note on Tuesday, December 17th. They set an "outperform" rating and a $75.00 price objective on the stock. Canaccord Genuity Group reissued a "hold" rating and issued a $80.00 target price (up from $74.00) on shares of Inari Medical in a research note on Tuesday. Stifel Nicolaus assumed coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They set a "hold" rating and a $50.00 price target on the stock. Finally, Robert W. Baird reiterated a "neutral" rating and issued a $80.00 price target (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Inari Medical currently has an average rating of "Hold" and a consensus price target of $68.00.

Inari Medical Stock Down 0.2 %

Shares of NARI stock traded down $0.15 during trading on Wednesday, reaching $79.30. The company's stock had a trading volume of 11,583,187 shares, compared to its average volume of 10,284,225. Inari Medical has a one year low of $36.73 and a one year high of $79.69. The business has a fifty day moving average price of $52.85 and a 200-day moving average price of $48.92. The company has a market cap of $4.64 billion, a price-to-earnings ratio of -58.74 and a beta of 0.97.

Insider Transactions at Inari Medical

In related news, Director William Hoffman sold 40,000 shares of the firm's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the transaction, the director now directly owns 601,233 shares of the company's stock, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the sale, the chief executive officer now directly owns 439,310 shares of the company's stock, valued at $24,289,449.90. This represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,000 shares of company stock worth $10,527,870. Company insiders own 10.60% of the company's stock.

Institutional Investors Weigh In On Inari Medical

A number of large investors have recently added to or reduced their stakes in NARI. Jennison Associates LLC lifted its position in shares of Inari Medical by 63.2% during the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock valued at $65,021,000 after acquiring an additional 610,468 shares during the period. Vestal Point Capital LP raised its stake in Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock valued at $63,922,000 after purchasing an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company's stock worth $71,324,000 after purchasing an additional 786,691 shares during the period. Armistice Capital LLC grew its stake in Inari Medical by 353.1% during the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company's stock worth $48,595,000 after buying an additional 786,501 shares in the last quarter. Finally, Bamco Inc. NY increased its holdings in Inari Medical by 29.5% in the 3rd quarter. Bamco Inc. NY now owns 1,006,129 shares of the company's stock valued at $41,493,000 after buying an additional 228,977 shares during the period. Institutional investors and hedge funds own 90.98% of the company's stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.